Lansoprazole

Generic Name: Lansoprazole

Brand Names: Prevacid, Prevpac

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄F_₃N_₃O_₂S

CAS Number: 103577-45-3

Unique Ingredient Identifier: 0K5C5T2QPG

Background: Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.

Indication: Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis. Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).

Associated Conditions: Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis

Associated Therapies: -

Clinical Trials

Lansoprazole 30 mg DR Capsule Fasting Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lansoprazole
Drug: Prevacid®

First Posted Date: 2010-01-11

Last Posted Date: 2010-12-08

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 56

Registration Number: NCT01045967

Locations: 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States

Lansoprazole 30 mg DR Capsule Replicate Food Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Prevacid®
Drug: Lansoprazole

First Posted Date: 2010-01-11

Last Posted Date: 2010-12-08

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 50

Registration Number: NCT01046084

Locations: 🇺🇸
Gateway Medical Research, Inc., St. Charles, Missouri, United States

Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Prevacid®
Drug: Lansoprazole

First Posted Date: 2010-01-11

Last Posted Date: 2010-12-08

Lead Sponsor: Teva Pharmaceuticals USA

Target Recruit Count: 50

Registration Number: NCT01046253

Locations: 🇺🇸
Gateway Medical Research, Inc., St. Charles, Missouri, United States

Lansoprazole for Subgroups of Functional Dyspepsia

Phase 4

Terminated

Conditions: Functional Dyspepsia

Interventions: Drug: placebo
Drug: Lansoprazole

First Posted Date: 2009-12-29

Last Posted Date: 2014-04-15

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 30

Registration Number: NCT01040455

Locations: 🇨🇳
E-Da Hospital, Kaohsiung, Taiwan
🇨🇳
National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan
🇨🇳
Veterans General Hospital-Taipei, Taipei, Taiwan

and more 1 locations